U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C27H27N7O2S.ClH
Molecular Weight 550.075
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PIDNARULEX HYDROCHLORIDE

SMILES

Cl.CN1CCCN(CC1)C2=NC3=C(C=C2)C(=O)C(C(=O)NCC4=NC=C(C)N=C4)=C5SC6=CC=CC=C6N35

InChI

InChIKey=YCGHUQKYOCALNJ-UHFFFAOYSA-N
InChI=1S/C27H27N7O2S.ClH/c1-17-14-29-18(15-28-17)16-30-26(36)23-24(35)19-8-9-22(33-11-5-10-32(2)12-13-33)31-25(19)34-20-6-3-4-7-21(20)37-27(23)34;/h3-4,6-9,14-15H,5,10-13,16H2,1-2H3,(H,30,36);1H

HIDE SMILES / InChI

Molecular Formula C27H27N7O2S
Molecular Weight 513.614
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/27391441

CX-5461 represents an innovative-targeted agent with numerous differentiating features when compared to current options for treatment of hematologic cancers. CX-5461 is a first-in-class small molecule inhibitor of RNA polymerase I (Pol I) that triggers the nucleolar stress surveillance pathways to activate p53, without causing direct DNA damage. Molecular studies demonstrate that CX-5461 inhibits the initiation stage of rRNA synthesis and induces both senescence and autophagy, but not apoptosis, through a p53-independent process in solid tumor cell lines. Currently, CX-5461 is in clinical trial for patients with advanced hematological malignancies.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
142.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1707 ng/mL
170 mg/m² 1 times / 3 weeks multiple, intravenous
dose: 170 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
CX-5461 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1358 ng/mL
250 mg/m² 1 times / 3 weeks multiple, intravenous
dose: 250 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
CX-5461 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
17943 ng × h/mL
170 mg/m² 1 times / 3 weeks multiple, intravenous
dose: 170 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
CX-5461 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
28612 ng × h/mL
250 mg/m² 1 times / 3 weeks multiple, intravenous
dose: 250 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
CX-5461 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
45.5 h
170 mg/m² 1 times / 3 weeks multiple, intravenous
dose: 170 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
CX-5461 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
83.3 h
250 mg/m² 1 times / 3 weeks multiple, intravenous
dose: 250 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
CX-5461 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

CX5461 as intravenous infusion on day 1 and day 8 every 4 weeks. A day 1 every 3 weeks schedule may be used if the day 1 and day 8 every 4 weeks schedule is not tolerable.
Route of Administration: Intravenous
ChIP analysis was employed to investigate the effects of CX-5461 on the association of various components of the Pol I multiprotein complex with the rDNA promoter. Treatment of HCT-116 colorectal carcinoma cells, A375, or MIA PaCa-2 with 2 μmol/L CX-5461 resulted in 40% to 60% reduction of the Pol I enzyme association with the rDNA promoter. Further, CX-5461 significantly depleted the binding of Pol I transcription factors (TF) to the rDNA promoter in HCT-116 cells, with the TBP (is a member of both Pol I and Pol II transcription machineries) and TAFI110 subunits of SL1 (TBP, TAFI110, TAFI63) being most overtly affected. To ensure that CX-5461 selectively inhibits rRNA transcription but not DNA or protein synthesis, HCT-116, A375, and MIA PaCa-2 cells were preincubated with 10 μmol/L CX-5461 for 60 minutes. In dose–response studies, the IC50 for inhibition of DNA synthesis in A375 and MIA PaCa-2 cell lines ranged from 16.8 to 27.9 μmol/L, whereas a high-test dose of 30 μmol/L CX-5461 had no significant effect on proteins synthesis. Thus, CX-5461 possesses 250- to 300-fold selectivity for inhibition of rRNA transcription versus DNA replication and protein translation.
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:34:21 GMT 2023
Edited
by admin
on Sat Dec 16 16:34:21 GMT 2023
Record UNII
S2L1QGG7Y7
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PIDNARULEX HYDROCHLORIDE
Common Name English
CX-5461 HYDROCHLORIDE
Code English
5H-BENZOTHIAZOLO(3,2-A)(1,8)NAPHTHYRIDINE-6-CARBOXAMIDE, 2-(HEXAHYDRO-4-METHYL-1H-1,4-DIAZEPIN-1-YL)-N-((5-METHYL-2-PYRAZINYL)METHYL)-5-OXO-, HYDROCHLORIDE (1:1)
Systematic Name English
Code System Code Type Description
PUBCHEM
131699687
Created by admin on Sat Dec 16 16:34:21 GMT 2023 , Edited by admin on Sat Dec 16 16:34:21 GMT 2023
PRIMARY
CAS
2101314-20-7
Created by admin on Sat Dec 16 16:34:21 GMT 2023 , Edited by admin on Sat Dec 16 16:34:21 GMT 2023
PRIMARY
FDA UNII
S2L1QGG7Y7
Created by admin on Sat Dec 16 16:34:21 GMT 2023 , Edited by admin on Sat Dec 16 16:34:21 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY